Skip to main content

ALKS

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

ALKS Price
Price Chart

Forward-looking statistics

Beta
0.47
Risk
33.41%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees2K
Market cap$4.0B

Fundamentals

Enterprise value$3.9B
Revenue$1.5B
Revenue per employee
Profit margin23.30%
Debt to equity4.90

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$2.10
Dividend per share
Revenue per share$9.22
Avg trading volume (30 day)$50M
Avg trading volume (10 day)$57M
Put-call ratio

Macro factor sensitivity

Growth+1.7
Credit+3.8
Liquidity-1.6
Inflation-0.2
Commodities+0.0
Interest Rates-1.8

Valuation

Dividend yield0.00%
PEG Ratio14.35
Price to sales3.14
P/E Ratio14.35
Enterprise Value to Revenue2.58
Price to book3.15

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day
Ex. dividend day

News

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.

Zacks Investment Research (July 2, 2025)
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates

ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations.

Zacks Investment Research (May 2, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free